Publication Type Review
Authors Goldberg J, Garton A, Singh S, Kirnaz S, Sommer F, Carnevale J, Atalay B, Medary B, McGrath L, Härtl R
Journal World Neurosurg
Volume 157
Pagination 274-281
Date Published 01/01/2022
ISSN 1878-8769
Keywords Biological Products, Biomechanical Phenomena, Intervertebral Disc Degeneration
Abstract There are numerous innovative and promising approaches aimed at slowing, reversing, or healing degenerative disc disease. However, multiple treatment-specific impediments slow progress toward realizing the benefits of these therapies. First, the exact pathophysiology underlying degenerative disc disease remains complicated and challenging to study. In addition, the study of the spine and intervertebral disc in animal models is difficult to translate to humans, hindering the utility of preclinical research. Biological treatments are subject to the complex biomechanical environment in which native discs degenerate. The regulatory approval environment for these therapeutics will likely involve a high degree of scrutiny. Finally, patient selection and assessment of outcomes are a particular challenge in this clinical setting.
DOI 10.1016/j.wneu.2021.09.067
PubMed ID 34929785
Back to Top